J&J has picked up 14% since we recommended it early this year, driven by strong execution and optimism regarding a recent acquisition that could buttress its portfolio of treatments.

While J&J has cautiously guided lower on its revenues, it nonetheless expects higher earnings in 2017.

Today, we explore if J&J shareholders should prune back their positions, or hold for more growth.

READ FULL ARTICLE HERE